• Je něco špatně v tomto záznamu ?

Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes

S. Di Palma, RH. Simpson, C. Marchiò, A. Skálová, M. Ungari, A. Sandison, S. Whitaker, S. Parry, JS. Reis-Filho,

. 2012 ; 61 (4) : 629-43.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028554

AIMS: The aim of this study was to devise a molecular classification for salivary duct carcinomas (SDCs) based on the similarities between SDCs and breast carcinomas and on characteristics of the microarray-based gene expression profiling-defined molecular subtypes of breast cancer. METHODS AND RESULTS: Forty-two pure salivary duct carcinomas, 35 of which contained an in-situ component as defined by histological review and/or immunohistochemical analysis, were stained with antibodies for oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6. Based on these markers, tumours were classified into HER2, luminal androgen receptor-positive, basal-like, luminal and indeterminate phenotype. Analysis revealed that 16.7%, 69%, 4.8%, 9.5% and 0% were of HER2, luminal androgen receptor-positive, basal-like, indeterminate and luminal phenotype, respectively. The in-situ and invasive components displayed the same molecular subtype in all but one case. CONCLUSION: Salivary duct carcinomas can be classified into molecular subgroups approximately equivalent to those in the breast. We also report on the existence of a subgroup of bona fide pure salivary duct carcinomas that have a 'basal-like' phenotype. Understanding the phenotypic complexity of SDCs may help to expedite the identification of novel therapeutic targets for these aggressive tumours.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028554
003      
CZ-PrNML
005      
20161024101756.0
007      
ta
008      
161005s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1365-2559.2012.04252.x $2 doi
024    7_
$a 10.1111/j.1365-2559.2012.04252.x $2 doi
035    __
$a (PubMed)22882517
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Di Palma, Silvana $u Department of Histopathology, Royal Surrey County Hospital, Guildford, SurreyDivision of Clinical Medicine, University of Surrey, Guildford, SurreyDepartment of Histopathology, Royal Devon and Exeter Hospital, Exeter, DevonThe Breakthrough Breast Cancer Research Centre - Institute of Cancer Research, London, UKDepartment of Pathology, Faculty of Medicine, Charles University in Prague, Plzeň, Czech RepublicDepartment of Pathology, Spedali Civili Brescia, Brescia, ItalyDepartment of Histopathology, Imperial College Healthcare Trust, Charing Cross Hospital, LondonDepartment of Oncology, St Lukes Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.
245    10
$a Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes / $c S. Di Palma, RH. Simpson, C. Marchiò, A. Skálová, M. Ungari, A. Sandison, S. Whitaker, S. Parry, JS. Reis-Filho,
520    9_
$a AIMS: The aim of this study was to devise a molecular classification for salivary duct carcinomas (SDCs) based on the similarities between SDCs and breast carcinomas and on characteristics of the microarray-based gene expression profiling-defined molecular subtypes of breast cancer. METHODS AND RESULTS: Forty-two pure salivary duct carcinomas, 35 of which contained an in-situ component as defined by histological review and/or immunohistochemical analysis, were stained with antibodies for oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6. Based on these markers, tumours were classified into HER2, luminal androgen receptor-positive, basal-like, luminal and indeterminate phenotype. Analysis revealed that 16.7%, 69%, 4.8%, 9.5% and 0% were of HER2, luminal androgen receptor-positive, basal-like, indeterminate and luminal phenotype, respectively. The in-situ and invasive components displayed the same molecular subtype in all but one case. CONCLUSION: Salivary duct carcinomas can be classified into molecular subgroups approximately equivalent to those in the breast. We also report on the existence of a subgroup of bona fide pure salivary duct carcinomas that have a 'basal-like' phenotype. Understanding the phenotypic complexity of SDCs may help to expedite the identification of novel therapeutic targets for these aggressive tumours.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a karcinom $x klasifikace $x genetika $x patologie $7 D002277
650    _2
$a karcinom in situ $x klasifikace $x genetika $x patologie $7 D002278
650    _2
$a duktální karcinom $x klasifikace $x genetika $x patologie $7 D044584
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ $7 D017403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a fenotyp $7 D010641
650    _2
$a receptor erbB-2 $x analýza $x biosyntéza $x genetika $7 D018719
650    _2
$a androgenní receptory $x analýza $x biosyntéza $x genetika $7 D011944
650    _2
$a vývody slinných žláz $x patologie $7 D018987
650    _2
$a nádory slinných žláz $x klasifikace $x genetika $x patologie $7 D012468
650    _2
$a čipová analýza tkání $7 D046888
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Simpson, Roderick H W
700    1_
$a Marchiò, Caterina
700    1_
$a Skálová, Alena
700    1_
$a Ungari, Marco
700    1_
$a Sandison, Ann
700    1_
$a Whitaker, Stephen
700    1_
$a Parry, Suzanne
700    1_
$a Reis-Filho, Jorge S
773    0_
$w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 61, č. 4 (2012), s. 629-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22882517 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161024102208 $b ABA008
999    __
$a ok $b bmc $g 1166868 $s 953184
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 61 $c 4 $d 629-43 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Možnosti archivace